Cargando…
Designer receptor technology for the treatment of epilepsy
Epilepsy remains refractory to medical treatment in ~30% of patients despite decades of new drug development. Neurosurgery to remove or disconnect the seizure focus is often curative but frequently contraindicated by risks of irreversible impairment to brain function. Novel therapies are therefore r...
Autores principales: | Lieb, Andreas, Weston, Mikail, Kullmann, Dimitri M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558262/ https://www.ncbi.nlm.nih.gov/pubmed/31078519 http://dx.doi.org/10.1016/j.ebiom.2019.04.059 |
Ejemplares similares
-
In vivo CRISPRa decreases seizures and rescues cognitive deficits in a rodent model of epilepsy
por: Colasante, Gaia, et al.
Publicado: (2020) -
Biochemical autoregulatory gene therapy for focal
epilepsy
por: Lieb, Andreas, et al.
Publicado: (2018) -
Semiology, clustering, periodicity and natural history of seizures in an experimental occipital cortical epilepsy model
por: Chang, Bao-Luen, et al.
Publicado: (2018) -
Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics
por: Weston, Mikail, et al.
Publicado: (2019) -
Epilepsy Gene Therapy Using an Engineered Potassium Channel
por: Snowball, Albert, et al.
Publicado: (2019)